Literature DB >> 21691811

Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.

Laura Guasch1, Esther Sala, Cristina Valls, Mayte Blay, Miquel Mulero, Lluís Arola, Gerard Pujadas, Santiago Garcia-Vallvé.   

Abstract

Peroxisome Proliferator-Activated Receptor γ (PPARγ) full agonists are molecules with powerful insulin-sensitizing action that are used as antidiabetic drugs. Unfortunately, these compounds also present various side effects. Recent results suggest that effective PPARγ agonists should show a low transactivation activity but a high binding affinity to inhibit phosphorylation at Ser273. We use several structure activity relationship studies of synthetic PPARγ agonists to explore the different binding features of full and partial PPARγ agonists with the aim of differentiating the features needed for binding and those needed for the transactivation activity of PPARγ. Our results suggest that effective partial agonists should have a hydrophobic moiety and an acceptor site with an appropriate conformation to interact with arm II and establish a hydrogen bond with Ser342 or an equivalent residue at arm III. Despite the fact that interactions with arm I increase the binding affinity, this region should be avoided in order to not increase the transactivation activity of potential PPARγ partial agonists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691811     DOI: 10.1007/s10822-011-9446-9

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  34 in total

1.  Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists.

Authors:  James F Dropinski; Taro Akiyama; Monica Einstein; Bahanu Habulihaz; Tom Doebber; Joel P Berger; Peter T Meinke; Guo Q Shi
Journal:  Bioorg Med Chem Lett       Date:  2005-11-15       Impact factor: 2.823

2.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

Review 3.  Structural insight into PPARgamma ligands binding.

Authors:  A Farce; N Renault; P Chavatte
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

4.  Novel method for generating structure-based pharmacophores using energetic analysis.

Authors:  Noeris K Salam; Roberto Nuti; Woody Sherman
Journal:  J Chem Inf Model       Date:  2009-10       Impact factor: 4.956

5.  Selective PPARgamma modulators with improved pharmacological profiles.

Authors:  Kun Liu; Regina M Black; John J Acton; Ralph Mosley; Sheryl Debenham; Ramon Abola; Meng Yang; Richard Tschirret-Guth; Lawrence Colwell; Cherrie Liu; Margaret Wu; Chuanlin F Wang; Karen L MacNaul; Margaret E McCann; David E Moller; Joel P Berger; Peter T Meinke; A Brian Jones; Harold B Wood
Journal:  Bioorg Med Chem Lett       Date:  2005-05-16       Impact factor: 2.823

6.  Horizontal gene transfer in glycosyl hydrolases inferred from codon usage in Escherichia coli and Bacillus subtilis.

Authors:  S Garcia-Vallvé; J Palau; A Romeu
Journal:  Mol Biol Evol       Date:  1999-09       Impact factor: 16.240

7.  Highly functionalized 7-azaindoles as selective PPAR gamma modulators.

Authors:  Sheryl D Debenham; Audrey Chan; Fiona Waiyu Lau; Weiguo Liu; Harold B Wood; Karen Lemme; Lawrence Colwell; Bahanu Habulihaz; Taro E Akiyama; Monica Einstein; Thomas W Doebber; Neelam Sharma; Chaunlin F Wang; Margaret Wu; Joel P Berger; Peter T Meinke
Journal:  Bioorg Med Chem Lett       Date:  2008-07-30       Impact factor: 2.823

Review 8.  PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?

Authors:  P L Feldman; M H Lambert; B R Henke
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

9.  Characterization of new PPARgamma agonists: benzimidazole derivatives - the importance of position 2.

Authors:  Matthias Goebel; Bart Staels; Thomas Unger; Ulrich Kintscher; Ronald Gust
Journal:  ChemMedChem       Date:  2009-07       Impact factor: 3.466

10.  Partial agonists activate PPARgamma using a helix 12 independent mechanism.

Authors:  John B Bruning; Michael J Chalmers; Swati Prasad; Scott A Busby; Theodore M Kamenecka; Yuanjun He; Kendall W Nettles; Patrick R Griffin
Journal:  Structure       Date:  2007-10       Impact factor: 5.006

View more
  12 in total

1.  Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.

Authors:  Travis S Hughes; Michael J Chalmers; Scott Novick; Dana S Kuruvilla; Mi Ra Chang; Theodore M Kamenecka; Mark Rance; Bruce A Johnson; Thomas P Burris; Patrick R Griffin; Douglas J Kojetin
Journal:  Structure       Date:  2012-01-11       Impact factor: 5.006

2.  Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro.

Authors:  Wei Yi; Jingjing Shi; Guanguan Zhao; X Edward Zhou; Kelly Suino-Powell; Karsten Melcher; H Eric Xu
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

3.  Dihydrosanguinarine Enhances Glucose Uptake in Mouse 3T3-L1 Cells.

Authors:  Yit-Lai Chow; Yuko Iwata; Fumihiko Sato
Journal:  ACS Omega       Date:  2017-10-19

4.  Probing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties.

Authors:  Shalini Muralikumar; Umashankar Vetrivel; Angayarkanni Narayanasamy; Undurti N Das
Journal:  Lipids Health Dis       Date:  2017-01-21       Impact factor: 3.876

Review 5.  Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer's Disease.

Authors:  Manoj Govindarajulu; Priyanka D Pinky; Jenna Bloemer; Nila Ghanei; Vishnu Suppiramaniam; Rajesh Amin
Journal:  PPAR Res       Date:  2018-10-21       Impact factor: 4.964

6.  Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation.

Authors:  Laura Guasch; Esther Sala; Anna Castell-Auví; Lidia Cedó; Klaus R Liedl; Gerhard Wolber; Markus Muehlbacher; Miquel Mulero; Montserrat Pinent; Anna Ardévol; Cristina Valls; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

7.  Polyacetylenes from Notopterygium incisum--new selective partial agonists of peroxisome proliferator-activated receptor-gamma.

Authors:  Atanas G Atanasov; Martina Blunder; Nanang Fakhrudin; Xin Liu; Stefan M Noha; Clemens Malainer; Matthias P Kramer; Amina Cocic; Olaf Kunert; Andreas Schinkovitz; Elke H Heiss; Daniela Schuster; Verena M Dirsch; Rudolf Bauer
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

8.  Identification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activity.

Authors:  Laura Guasch; Esther Sala; Miquel Mulero; Cristina Valls; Maria Josepa Salvadó; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

9.  Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma.

Authors:  Eva-Maria Pferschy-Wenzig; Atanas G Atanasov; Clemens Malainer; Stefan M Noha; Olaf Kunert; Daniela Schuster; Elke H Heiss; Nicholas H Oberlies; Hildebert Wagner; Rudolf Bauer; Verena M Dirsch
Journal:  J Nat Prod       Date:  2014-03-05       Impact factor: 4.050

Review 10.  Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review.

Authors:  Limei Wang; Birgit Waltenberger; Eva-Maria Pferschy-Wenzig; Martina Blunder; Xin Liu; Clemens Malainer; Tina Blazevic; Stefan Schwaiger; Judith M Rollinger; Elke H Heiss; Daniela Schuster; Brigitte Kopp; Rudolf Bauer; Hermann Stuppner; Verena M Dirsch; Atanas G Atanasov
Journal:  Biochem Pharmacol       Date:  2014-07-30       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.